SciRhom raises €63 million to advance iRhom2-targeting therapies for autoimmune diseases
Munich-based biopharmaceutical company SciRhom GmbH has secured a substantial €63 million (US$70 million) in Series A financing to accelerate the development of its pioneering iRhom2-targeting antibodies for autoimmune disorders. The oversubscribed funding round, co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, will propel the company’s lead candidate toward clinical proof-of-concept […]